Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.

24 established melanoma cell cultures were screened for their secretion of plasminogen activators and plasminogen activator inhibitors into the culture medium by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by conventional and reverse fibrin autography. Among the cell lines investigated, 22 cell lines predominantly secreting tissue type plasminogen activator (t-PA) and four cell lines additionally secreting urokinase were found. The conditioned media of two cell lines (KRFM and MJZJ) were found to contain plasminogen activator inhibitor (PAI) activity at a Mr position of approximately 50,000. The PAI of one of the two melanoma cell (MJZJ)-conditioned media found to contain PAI activity was purified to apparent homogeneity employing concanavalin A-Sepharose chromatography, gel filtration on Sephadex G-150, chromatography on Affi-Gel blue, and affinity chromatography on a Sepharose 4B immobilized monoclonal anti-t-PA IgG column. The purified melanoma PAI was found to be a single chain protein, acid stable, immunologically related to the endothelial derived PAI. In contrast to endothelial PAI, melanoma PAI presented itself in the conditioned media of the melanoma cells and in the purified preparation to an appreciable extent in its active form.

• Publication year

  1986

• Venue

  Journal of Biological Chemistry

• Publication date

  1986-11-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/s0021-9258(18)66894-2PMID 3490474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasminogen activator inhibitor in the blood of patients with coronary artery disease.

  1985cited by this paper
• Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.

  1985cited by this paper
• Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.

  1985cited by this paper
• Purification of a Specific Placental Plasminogen Activator Inhibitor by Monoclonal Antibody and Its Complex Formation with Plasminogen Activator

  1985cited by this paper
• Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator.

  1985cited by this paper
• Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor.

  1984cited by this paper
• Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.

  1984cited by this paper
• Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis.

  1984cited by this paper
• Characterization of a specific anti-human urokinase antibody: development of a sensitive competition radioimmunoassay for urokinase antigen.

  1984cited by this paper
• Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor

  1984cited by this paper
• Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.

  1984cited by this paper
• Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex.

  1984cited by this paper
• Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.

  1984cited by this paper
• Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium.

  1984cited by this paper
• Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.

  1983cited by this paper
• Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells.

  1983cited by this paper
• Studies on the kinetics of plasminogen activation by tissue plasminogen activator.

  1982cited by this paper
• Cultured bovine endothelial cells produce both urokinase and tissue- type plasminogen activators

  1982cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper
• Kinetics of the Reaction Between Urokinase and an Inhibitor of Fibrinolysis from Placental Tissue

  1982cited by this paper
• Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.

  1981cited by this paper
• An Inhibitor Of Plasminogen Activator In Rabbit Endothelial Cells

  1981cited by this paper
• Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

  1981cited by this paper
• Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells.

  1980cited by this paper
• Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.

  1979cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.

  1978cited by this paper
• A study of proteases and protease-inhibitor complexes in biological fluids

  1978cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Inhibition of plasminogen activators by naturally occurring inhibitors in man.

  1972cited by this paper
• Inhibitory Effect of Placenta on Plasminogen Activation in Human Organ Culture 1

  1972cited by this paper
• Partial purification and properties of urokinase inhibitor from human placenta.

  1970cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Plasminogen: Purification from Human Plasma by Affinity Chromatography

  1970cited by this paper
• N-Terminal Disulphide Knot of Human Fibrinogen

  1968cited by this paper
• Urokinase Inhibitor in Human Placenta

  1968cited by this paper

• Competition of activated protein C and urokinase for a heparindependent inhibitor<link href="#fsb2002007007-note-0001">¹</link>

  2020cites this paper
• C\fokine Regulation of the Synthesis of Plasminogen Activator lnhibitor-2 by Human Vascular Endothelial Cells Gomparison with Plasminogen Activator lnhibitor-l Synthesis

  2018cites this paper
• and In Vivo

  2017cites this paper
• Bernd Binder (January 7, 1945 – August 28, 2010)

  2010cites this paper
• functionally active type 1 plasminogen activator inhibitor Extracellular matrix of cultured bovine aortic endothelial cells contains

  2010cites this paper
• Myocardial Infarction Occurs with a Similar 24 h Pattern in the 4G/5G Versions of Plasminogen Activator Inhibitor-1

  2009cites this paper
• Plasminogen Activator Inhibitor 1 in Platelets - Studies of Synthesis, Activity, and Glycosylation Patterns

  2008cites this paper
• Signaling in endothelial cells: 10 years Department of Vascular Biology and Thrombosis Research at the Medical University Vienna

  2007cites this paper
• Complex Formation Between Urokinase and Plasma Protein C Inhibitor In Vitro

  2005cites this paper
• murine monoclonal antibody-based enzyme-linked immunosorbent assay Measurement of plasminogen activator inhibitor 1 in biologic fluids with a

  2005cites this paper
• In vitro induction of endothelial cell fibrinolytic alterations by Nigella sativa.

  2005cites this paper
• In vitro decreases of the fibrinolytic potential of cultured human fibrosarcoma cell line, HT1080, by Nigella sativa oil.

  2005cites this paper
• Plasminogen activator inhibitor-1.

  2004cites this paper
• The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors

  2004cites this paper
• Plasminogen Activators Inhibitors

  2003cites this paper
• Assessment of plasminogen activator inhibitor type 2 (PAI-2) as an imaging and therapeutic agent of human cancer

  2001cites this paper
• Glycosylation dependent conformational transitions in plasminogen activator inhibitor-1: evidence for the presence of two active conformations

  2000cites this paper
• Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).

  1998cites this paper
• The International Standard for Plasminogen Activator Inhibitor-1 (PAI-1) Activity

  1996cites this paper
• The plasminogen activation system in melanoma cell lines and in melanocytic lesions.

  1996cites this paper
• Azelaic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro.

  1996cites this paper
• Retinal control on the axial length mediated by transforming growth factor-beta in chick eye.

  1996cites this paper
• The urokinase plasminogen activator (u-PA) and its inhibitor (PAI-1) in embryo-fetal bone formation in the human: an immunohistochemical study

  1995cites this paper
• Standards in Fibrinolysis – Current Status and Future Challenges

  1995cites this paper
• Hepatocyte Growth Factor Stimulates Expression of Plasminogen Activator Inhibitor Type 1 and Tissue Factor in HepG 2 Cells

  1994cites this paper
• Cytokine modulation of plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down-regulation by tumor necrosis factor alpha and up-regulation by transforming growth factor-B basic fibroblast growth factor.

  1994cites this paper
• Immunohistochemical Localization of Plasminogen Activator Inhibitor Type 1 in Human Brain Tumors

  1994cites this paper
• Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli.

  1994cites this paper
• Effect of type-1 plasminogen activator inhibitor on human leukocyte elastase.

  1994cites this paper
• Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells.

  1994cites this paper
• Plasminogen activator inhibitor-1 in the pathogenesis of delayed radiation damage in rat spinal cord in vivo.

  1994cites this paper
• Involvement of antipain-sensitive protease activity in suppression of UV-mutagenicity by human interferon-alpha.

  1994cites this paper
• Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.

  1994cites this paper
• Regulation of plasminogen activator inhibitor-1 levels in human monocytes.

  1993cites this paper
• Cytokine Regulation of the Synthesis of Plasminogen Activator Inhibitor-2 by Human Vascular Endothelial Cells

  1993cites this paper
• Interleukin-4 stimulates expression of urokinase-type-plasminogen activator in cultured human foreskin microvascular endothelial cells.

  1993cites this paper
• Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes.

  1993cites this paper
• Thrombin Stimulates Expression of Tissue-Type Plasminogen Activator and Plasminogen Activator lnhibitor Type 1 in Cultured Human Vascular Smooth Muscle Cells

  1993cites this paper
• Binding of tissue‐type plasminogen activator to human melanoma cells

  1993cites this paper
• Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor.

  1993cites this paper
• Contrasting effects of transforming growth factor-beta and IL-1 on the regulation of plasminogen activator inhibitors in human synovial fibroblasts.

  1993cites this paper
• Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells.

  1993cites this paper
• Induction of Proteases and Their Inhibitors in Cell Lines of Different Metastatic Potentials and Activated Oncogenes

  1993cites this paper
• Endogenous Fibrinolytic System in Chronic Large‐Vessel Thromboembolic Pulmonary Hypertension

  1992cites this paper
• Independent regulation of plasminogen activator inhibitor 2 and plasminogen activator inhibitor 1 in human synovial fibroblasts.

  1992cites this paper
• Proteinases and Proteinase Inhibitors

  1992cites this paper
• Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.

  1992cites this paper
• Purification and characterization of active and latent forms of recombinant plasminogen activator inhibitor 1 produced in Escherichia coli.

  1992cites this paper
• The Peritoneum

  1992cites this paper
• Plasminogen Activator Inhibitor Type 1: Biochemistry and Evidence for Modulation of Fibrinolysis In Vivo

  1992cites this paper
• Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activator.

  1991cites this paper
• Detection of specific forms of plasminogen activator inhibitor type 1-by monoclonal antibodies

  1991cites this paper
• A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor.

  1991cites this paper
• The formation of complexes between human plasminogen activator inhibitor-1 (PAI-1) and sodium dodecyl sulfate: possible implication in the functional properties of PAI-1.

  1991cites this paper
• Inhibition of DNA synthesis and oncogene expression in tumor cells by the biological factor DIF.

  1991cites this paper
• Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro.

  1991cites this paper
• Microcarrier culture of bowes melanoma cells in serum‐free medium with Human plasma fraction IV‐4+ V

  1991cites this paper
• The Biochemistry, Cell and Molecular Biology of Type 1 Plasminogen Activator Inhibitor

  1991cites this paper
• Function of Receptor-Bound Urokinase

  1991cites this paper
• High-level synthesis of biologically active human plasminogen activator inhibitor type 1 (PAI-1) in Escherichia coli.

  1990cites this paper
• Purification and characterization of human plasminogen activator inhibitor type I expressed in Saccharomyces cerevisiae.

  1990cites this paper
• Plasminogen activator inhibitors: Biological effects

  1990cites this paper
• Relationship between plasma levels of components of the fibrinolytic system and acute‐phase reactants in patients with uterine malignancies

  1990cites this paper
• The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis

  1990cites this paper
• Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue.

  1990cites this paper
• Tissue plasminogen activator catalyzed Lys-plasminogen activation on heparin-inserted phospholipid liposomes.

  1990cites this paper
• Plasminogen activators, plasminogen activator inhibitor, and fibronectin in human granulosa cells and follicular fluid related to oocyte maturation and intrafollicular gonadotropin levels.

  1990cites this paper
• New Trends in Haemostasis

  1990cites this paper
• Concomitant Secretion by A431 Cells of Tissue Plasminogen Activator and a Specific Inhibitor Masks EGF Modulation of tPA Activity

  1990cites this paper
• The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

  1990cites this paper
• Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.

  1990cites this paper
• Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.

  1989cites this paper
• Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo.

  1989cites this paper
• Evaluation of Fibrinolytic Capacity in Plasma during Thrombolytic Therapy with Single (scu-PA) or Two-chain Urokinase Type Plasminogen Activator (tcu-PA) by a Combined Assay System for Urokinase Type Plasminogen Activator Antigen and Function

  1989cites this paper
• Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue-type plasminogen activator.

  1989cites this paper
• A comparison between activated protein C and des-1-41-light chain-activated protein C in reactions with type 1 plasminogen activator inhibitor.

  1989cites this paper
• Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.

  1989cites this paper
• Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors.

  1989cites this paper
• Influence of delivery on plasminogen activator inhibitor activity

  1989cites this paper
• Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.

  1989cites this paper
• Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.

  1989cites this paper
• Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes.

  1989cites this paper
• Fibrinolytic inhibitors from the experimental rat epithelioma.

  1989cites this paper
• Comparison of fibrinolytic activities of human and bovine endothelial cells.

  1988cites this paper
• Clot Lysis Mediated by Cultured Human Microvascular Endothelial Cells

  1988cites this paper
• An Enzyme-Linked Immunosorbent Assay (ELISA) Used to Study the Cellular Secretion of Endothelial Plasminogen Activator Inhibitor (PAI-1)

  1988cites this paper
• Low molecular weight fibrinolytic inhibitor in plasma of rats bearing Guerin epithelioma.

  1988cites this paper
• Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function.

  1988cites this paper
• Plasminogen activator inhibitors--a review.

  1988cites this paper
• Bovine endothelial cell plasminogen activator inhibitor. Purification and heat activation.

  1988cites this paper
• Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions.

  1988cites this paper
• Plasminogen activation: biochemistry, physiology, and therapeutics.

  1988cites this paper
• Competition of activated protein C and urokinase for a heparin‐dependent inhibitor 1

  1988cites this paper
• Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent, and guanidine-activated forms.

  1988cites this paper
• Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

  1988cites this paper
• Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).

  1988cites this paper
• Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors.

  1988cites this paper
• Protein C inhibitor/plasminogen activator inhibitor 3

  1988cites this paper
• Increased Plasma Levels of Urokinase-Type Plasminogen Activator With Endometrial and Cervical Cancer

  1988cites this paper
• Type 1 Plasminogen Activator Inhibitor and Its Potential Influence on Thrombolytic Therapy

  1988cites this paper